injury can predict ICD shocks and mortality in a large, community-based cohort of primary prevention ICD recipients with ischemic and nonischemic cardiomyopathy.
Methods

Study Design and Clinical Data Collection
The Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD) is a multicenter observational study of patients with systolic heart failure eligible for a primary prevention ICD. Details of the design and baseline characteristics of study participants have been described elsewhere 9 ; study participants underwent ICD implantation based on current guidelines. 10 The study enrolled 1189 participants. All centers obtained approval from their respective institutional review boards and all patients provided written informed consent.
PROSE-ICD participants were extensively phenotyped as previously described. 9 All patients underwent a baseline comprehensive history and cardiovascular examination along with a digitally recorded resting 12-lead ECG, a 5-minute 3-lead ECG, an echocardiogram and fasting blood collection. Study participants were evaluated twice a year. ICDs were also interrogated (in person or via remote transmission) to assess arrhythmic events. Patients who were not seen in clinic underwent a telephone interview to update history and medication use.
Serum Biomarker Analysis
Whole blood samples were collected and were kept at room temperature for 1 hour before centrifugation. Serum was stored at −80°C after quick freezing in liquid nitrogen. All biomarker measurements were made in serum. The inflammatory biomarkers included C-reactive protein (CRP), interleukin-6 (IL-6), IL-10, and tumor necrosis factor α receptor II. IL-6 (R&D Systems, Minneapolis, MN), IL-10 (R&D Systems), and CRP (ALPCO Diagnostics, Salem, NH) were measured with high-sensitivity ELISAs according to manufacturer's instructions (see Methods in the Data Supplement).
Study Outcomes
The primary outcome in PROSE-ICD was the occurrence of a first appropriate ICD shock for an adjudicated ventricular tachyarrhythmia. Detailed information from ICDs and patient outcomes were adjudicated as previously described. 9 For sensitivity analysis, we also examined the association of biomarkers with all-cause mortality after censoring participants at their first appropriate ICD shock.
Statistical Analyses
This was a post hoc analysis using unpaired t test, Wilcoxon rank-sum test, and χ 2 analyses as appropriate. Two-sided P<0.05 was considered statistically significant. Nominal P values were presented for analysis of each biomarker without adjustment for multiple comparisons.
Serum biomarkers were log-transformed before analyses and values expressed as medians. To evaluate the associations between serum biomarkers and end point events, we categorized each biomarker into quartiles. For cardiac troponin T (cTnT), cTnI, and myoglobin, because levels were undetectable in >25% of samples, participants were categorized into 4 groups (group 1, value 0; groups 2-4, tertiles of the nonzero values). We then used separate Cox proportional hazards regressions for each biomarker to estimate the hazard ratios comparing quartiles 2 to 4 to the first quartile of each biomarker. Cox models were adjusted for age, sex, race, enrollment center, current smoking, body mass index, ejection fraction, atrial fibrillation, hypertension, diabetes mellitus, chronic kidney disease (defined as a glomerular filtration rate, <60 mL/min per 1.73 m 2 ), device type (ICD, cardiac resynchronization therapy-defibrillator). Tests for linear trends across quartiles were conducted by including an ordinal variable with the median biomarker level of each quartile in the regression models. A combined score of the association between biomarker levels and study outcomes was created by adding the quartile ranks of all biomarkers that showed significant linear trends with appropriate ICD shocks or mortality. As a sensitivity analysis, death was treated as a competing risk for appropriate shock and the results were virtually the same (data not shown).
To examine whether the biomarker score improves prediction for mortality and shock beyond conventional clinical variables, we compared the performance of a basic model (a model with all clinical variables associated with either all-cause mortality or appropriate shock with a P<0.1 in the univariate analysis) with a model incorporating both the clinical variables and the serum biomarker risk score. Model discrimination was determined by c-statistics, and risk reclassification was assessed using both net reclassification improvement and integrated discrimination improvement, all accounted for censoring. 11, 12 In describing the net reclassification improvement, 5-year mortality and shock risk were categorized into 3 groups (<15%, 15%-50%, and >50% for mortality and <10%, 10%-20%, and >20% for appropriate shock) based on the observed distribution of risk in the cohort. Confidence intervals for these statistics were obtained using boot-strapping. We used the added variable version of Gronnesby and Borgan goodness-of-fit test for Cox regression, and a P>0.05 from the goodness-of-fit test indicates that predicted risk of the model is similar to the observed risk. All analyses were performed using STATA version 12 (StataCorp LP, College Station, TX).
Results
The average age (SD) of study participants at baseline was 60.6 (12.7) years, and detailed information on their clinical characteristics are noted in Table 1 . Most participants received a single-chamber ICD (55.1%) with 17.7% receiving dualchamber systems and 27.2% cardiac resynchronization therapy devices. The average lowest cutoff zone for tachycardia therapy was programmed to 185.2 beats per minute (14.6) .
After a median follow-up of 4.0 years, 137 subjects experienced an appropriate ICD shock and 343 participants died (incidence rates of 3.2 and 5.8 per 100 person-years, respectively). The majority of participants who died did not experience an appropriate ICD shock (294 of 343; 85.7%). Patients who experienced an appropriate ICD shock during follow-up were more likely to be men, white, current or former smokers, and to have higher body mass index, lower resting heart rate, and less hypertension and less likely to have chronic kidney disease ( Table 1 ). Patients who died during follow-up were more often men, current or former smokers, with New York Heart Association class III symptoms, longer QTc intervals and QRS durations, ischemic cardiomyopathy, atrial fibrillation, diabetes mellitus, hypertension, chronic kidney disease, lower body mass index, lower ejection fraction, and lower ICD therapy cutoff rates ( Table 2 ). Participants who died during follow-up were more frequently taking diuretics, aspirin, and angiotensin-converting enzyme inhibitor/angiotensin receptor blockers when compared with those who survived.
The number of events (eg, ICD shock and all-cause mortality) by quartile levels of biomarkers are noted in Table 3 . Median (Q1-Q3) levels of study biomarkers are shown in Table I in the Data Supplement . CRP and IL-6, cTnT and IL-6, and cTnT and cTnI showed pairwise Spearman correlation coefficients ≥0.4 ( Table II in the Data Supplement). In multivariable-adjusted models, the only biomarker showing a significant linear trend across quartiles with increased risk of appropriate ICD shocks was IL-6 ( Figure 1 ). The hazard ratio (95% confidence interval) for appropriate ICD shocks comparing the highest to the lowest quartiles of IL-6 was 2.23 (1.20-4.14) . When IL-6 was introduced as a log-transformed continuous variable in Cox models, the hazard ratio for an appropriate ICD shock comparing the 80th to the 20th percentile of the IL-6 distribution was 1.25 (0.98-1.60; Table III in the Data Supplement ).
In contrast to appropriate ICD shocks, CRP, IL-6, tumor necrosis factor α receptor II, pro-BNP, and cTnT showed significant linear trends for increased risk of mortality across quartiles ( Figure 1 ). The hazard ratios for all-cause mortality comparing the highest to the lowest quartiles of CRP, IL-6, tumor necrosis factor α receptor II, pro-BNP, and cTnT were 3 .63 (2.37-5.56), and 2.42 (1.74-3.37), respectively. The associations with all-cause mortality were similar when these analyses were repeated after censoring participants at their first appropriate ICD shock.
To understand the combined effect of biomarker levels on risk, we created a cumulative score by adding the quartile rank for the 5 biomarkers that showed a significant trend with all-cause mortality. The median score was 12 and ranged from 5 to 20. The proportions of participants with scores 5 to 9, 10 to 14, and 15 to 20 were 27.2, 38.1, and 27.2%, respectively. The rates of appropriate ICD shocks for patients with scores 5 to 9, 10 to 14, and 15 to 20 were 2.4, 3.2, and 4.1 per 100 person-years, respectively ( Figure 2 ). The corresponding rates for all-cause mortality were 1.8, 4.4, and 12.8 per 100 person-years, respectively.
To better understand the added potency of the serum biomarker risk score on discrimination for all-cause mortality, we incorporated the biomarker risk score into a set of clinical variables associated with an increased risk for death. By adding the biomarker score to the clinical variables, the c-statistics improved from 0.74 to 0.78 (difference in c-statistics, 0.04; 95% confidence interval, 0.02-0.06), with an net reclassification improvement of 15.7% (8.5%-22.3%) and the P value of the goodness-of-fit tests of 0.29 (Table 4 ). With respect to appropriate ICD shocks, adding the biomarker risk score resulted in only minor improvement in the prediction of appropriate shocks with c-statistics from 0.67 to 0.69 (difference in c-statistics, 0.02; 95% confidence interval, −0.008 to 0.04).
Given the recent studies demonstrating improvements in mortality and patient outcomes when ICDs are programmed with higher rate cutoffs, we performed a secondary analysis dividing the cohort into 2 groups: those with a rate cutoff <200 beats per minute (n=766) and those with a rate cutoff ≥200 beats per minute (n=221). When comparing the baseline characteristics between these 2 groups, patients with a lower cutoff rate were more likely to be older (average age, 62.8 versus 52.4), men (74.6% versus 64.1%), a smoker (68.9% versus 58.5%), have ischemic cardiomyopathy (58.0% versus 38.2%), diabetes mellitus (36.5% versus 27.6%), hypertension (66.2% versus 49.2%), and chronic kidney disease (31.7% versus 22.4%). Both the clinical score and the serum biomarker risk score performed better in patients with device cutoff ≥200 beats per minute, but the incremental improvement of the serum biomarker risk score (when added to the clinical variables only) in risk prediction was similar among the 2 groups (Table IV in the Data Supplement).
Discussion
In this large cohort study of stable patients with systolic heart failure who were candidates for primary prevention ICD implantation, serum biomarkers did poorly in predicting the likelihood of an appropriate ICD shock (primary end point). However, they did identify patients at increased risk of dying (secondary end point) without experiencing an appropriate ICD shock. Interestingly, IL-6 showed a significant trend predicting the occurrence of both appropriate ICD shocks and all-cause mortality, thus making it potentially less useful in identifying patients likely to experience an appropriate ICD shock. By using a composite score of these biomarkers, we were able to identify patients who were much more likely to die than to benefit from an appropriate ICD shock for a ventricular tachyarrhythmia. Furthermore, adding biomarker data to conventional clinical risk factors improved discrimination for all-cause mortality. Hence, our results suggest that inflammation, neurohumoral modulation, and cardiac injury assess complementary pathophysiological mechanisms that promote the progression of heart failure and ultimately increase the likelihood of death but they are poor predictors of ventricular arrhythmias that are effectively treated by ICD shocks. This profile of serum biomarkers allows for prospective identification of a subgroup of patients with a higher risk of death relative to their risk for an appropriate ICD shock.
The role of inflammation and neurohumoral activation in cardiovascular disease is well known and most strongly linked to atherosclerosis and heart failure. These studies have also provided insight into the predictive power of these biomarkers in the development of atrial and ventricular arrhythmias. [13] [14] [15] Although these findings may apply to healthy subjects, studies in patients with coronary disease or heart failure have been less definitive. [16] [17] [18] [19] In fact, one study demonstrated marginal predictive power of elevated CRP levels for heart failure mortality, but not for arrhythmic SCD. 19 The role of inflammation in predicting appropriate ICD therapy has also been inconsistent. Although some studies have demonstrated that elevated IL-6 and CRP levels were associated with ICD shocks, 20,21 and others have not. 22 This inconsistency is most likely explained by the small size and heterogeneity of the cohorts studied. Our findings demonstrate that CRP and other markers of systemic inflammation are inadequate predictors of the development of ICD shocks but can identify individuals who are at increased risk for nonarrhythmic modes of death. This latter point is particularly important given the controversy on the benefits of primary prevention ICDs and the need to develop more refined risk-stratification metrics.
The associations between pro-BNP levels and ICD shocks and all-cause mortality were similar to the relationship for markers of inflammation. Pro-BNP failed to predict the development of ICD shocks but did predict death after ICD implantation. Earlier studies suggested a strong link between BNP levels and ICD events, 23 but our findings are aligned with more recent studies which do not. 19, 24 From the perspective of overall mortality, our findings support an earlier study demonstrating that elevated levels of BNP are associated with an increased risk for death despite patients appearing clinically euvolemic. 25 Hence, obtaining information on BNP may provide additional discriminatory power in those at highest risk for death despite primary prevention ICD implantation.
Biomarkers for subclinical cardiac injury have long been recognized to predict major cardiovascular events in patients with cardiomyopathy. Several of these clinical studies occurred in cohorts where medical therapy for heart failure was not optimal by contemporary standards. Hence, the prognostic use of cardiac injury markers in well-treated patients with heart failure remains unclear. Our study demonstrates that markers for cardiac injury remain an important predictor of death after ICD implantation. The mechanisms remain unclear but previous studies have suggested that they may promote inflammation. 26 The limited sensitivity and specificity of using the ejection fraction as the primary means for SCD risk stratification has resulted in many individuals receiving ICDs deriving little benefit and also failing to identify individuals with relatively preserved function but remain at high SCD risk. 27 In fact, the CK-MB indicates creatine kinase-MB; cTnT, cardiac troponin T; hs-CRP, high-sensitivity C-reactive protein; ICD, implantable cardioverter defibrillators; IL, interleukin; pro-BNP, pro-brain natriuretic peptide; and TNF-α rec II, tumor necrosis factor α receptor II.
greatest number of SCD events occur in the general population without known heart disease, 28 thus the overall impact of the ICD on the population burden of SCD is relatively small. Hence, many have sought to develop a more personalized approach whereby the risk of an individual for SCD is not based on population-based observations but rather unique features of the particular individual. 29 Our findings add to these efforts by focusing on the biology of heart failure and shedding more light on potential mechanistic relationships between inflammation, neurohumoral activation, ongoing myocardial injury, and death. It is difficult to determine which of the 3 mechanisms predominates but our composite biomarker scoring schema suggests that they are in fact complementary to each other in predicting patient outcomes.
There are several limitations that need to be considered. First, we did not have a comparison cohort with heart failure who did not undergo ICD implantation. This was not a clinical trial and randomizing patients for ICD therapy in patients who fulfilled current guidelines would be unethical. We attempted to account for this by censoring patients who experienced appropriate ICD shocks before death for the all-cause mortality analysis. Despite this, we cannot exclude the possibility that the ICD prevented bradycardia-induced SCD because all devices provided pacing support. However, previous studies Figure 1 . Multivariable-adjusted hazard ratios (HR) for appropriate implantable cardioverter defibrillators (ICD) shocks (left), all-cause mortality (center), and all-cause mortality prior to receiving an appropriate ICD shock (right) by quartiles of biomarkers of inflammation, neurohumoral activation, and myocardial injury. HRs were adjusted for age, sex, race, study center, smoking status, body mass index, New York Heart Association class, atrial fibrillation, diabetes mellitus, hypertension, chronic kidney disease, and cardiac resynchronisation therapy device. CI indicates confidence interval; CK-MB, creatine kinase-MB; CRP, C-reactive protein; cTnT, cardiac troponin T; IL, interleukin; pro-BNP, pro-brain natriuretic peptide; and TNF-αRII, tumor necrosis factor α receptor II.
suggest that this mode of death is uncommon. 30 Second, this was a post hoc analysis and no analysis was performed on temporal changes in biomarker levels especially immediately before an end point event. Hence, these results alone do not resolve the inadequacy of ICD patient selection but may provide preliminary data in guiding the design of future prospective studies. Third, we do not have detailed information on what proportion of patients were at target with their heart failure medications or more detailed information on the detection duration parameters for ICD therapy delivery. Fourth, we excluded ATP therapy from the primary end point to identify the best surrogate for SCD and because of previous reports highlighting the prognostic importance of ICD shocks on mortality outcomes. 31 Fifth, the number of participants with appropriate ICD shocks was only 137, which limited our ability to identify modest predictors of risk. Finally, our observations on the relationship between biomarkers and appropriate ICD shocks and death may not be applicable in all populations at risk of SCD including those with preserved left ventricular function. Despite this, we think that our findings remain relevant to the majority of ICD recipients given that most have systolic dysfunction and improvements on currently available risk prediction models are urgently needed to refine application of this therapy to those who would benefit the most.
Using a limited set of serum biomarkers of inflammation, neurohumoral activation, and myocardial injury obtained at the time of enrollment, we identified patients who were likely to die after primary prevention ICD implantation without receiving ICD shocks for ventricular tachyarrhythmias. These findings may provide more specific criteria to identify those who are most likely to benefit from a primary prevention ICD but will need to be validated in large prospective clinical studies further.
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Figure 2.
Probability of survival free from appropriate implantable cardioverter defibrillators shocks (top) and all-cause mortality (bottom) as a function of a combined biomarker score. The combined score was created by adding the quartile rank for C-reactive protein, interleukin-6, tumor necrosis factor α receptor II, pro-brain natriuretic peptide, and cardiac troponin T. The median score was 12 (range, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The proportions of participants with scores 5 to 9, 10 to 14, and 15 to 20 were 27.2, 38.1, and 27.2%, respectively.
